This study involves taking a study drug calledbosutinib. The overall goals of this study are to find the bestdose of bosutinib that we can give safely, and to find out what effects, goodand/or bad, bosutinib has on children and adolescents with Chronic Myeloid Leukemia (CML).
The purpose of this study is to find out if alpelisib (BYL719;the “study drug”), is safe and effective (can help) people who have PIK3CA-related overgrowth spectrum (PROS) disease.
This study involves taking a study drug calledramucirumab. The overall goal of this study is to see how effective ramucirumabis when given in combination with gemcitabine and docetaxel in childrenand young adults with synovial sarcoma.
This study involves taking a study drug called ramucirumab.The overall goal of this study is to see how effective ramucirumab is whengiven in combination with cyclophosphamide and vinorelbine in children andyoung adults with desmoplastic small round cell tumor (DSRCT).
This phase 1/2 study will determine the safety, feasibility, and efficacy of CD33 CART cells following lymphodepleting chemotherapy in patients with acute myeloid leukemia (AML). Patients who are between ages 1 to 30 years with relapsed or refractory AML will be eligible for this study.
This study involves taking a study drug calledTAS-117. The overall goal of this study is to see if TAS-117 is a possibletreatment for advanced cancers with germline mutations in the PTEN gene.
This study involves taking a study drug called CUDC-907. CUDC-907 is an oral drug that blocks certainproteins in tumor cells; these proteins may be important in the growth of somecancers. The overall goals of this study are to evaluate the side effects andbenefits of CUDC-907 in patients with relapsed or treatment refractory solidtumor, brain tumor, or lymphoma, and to determine the best dose of CUDC-907 forchildren and adolescents. This studywill also look at the levels of CUDC-907 in the blood over time after a dose.
CHOP, in collaboration with Onyx Therapeutics, Inc., isconducting a study for children and young adults up to 21 years old, with relapsedor refractory acute lymphoblastic leukemia. This clinical trial is adding thestudy drug, Carfilzomib, to a standard relapse chemotherapy regimen. For moreinformation about this study, including specific eligibility criteria, pleasevisit clinicaltrials.gov and search for "NCT02303821". To hear moreabout this and other available trails or get any questions answered pleasecontact our Cancer Intake Specialist by phone at 267-426-0762 or email Oncointake@email.chop.edu.
This study involves taking a study drug called ALRN-6924. ALRN-6924is an investigational cancer treatment that activates p53, which suppresses thegrowth of tumors by blocking proteins in the cell called MDM2 and MDMX thatinhibit p53 from doing its job. The overall goals of thisstudy are to evaluate the side effects and benefits of ALRN-6924 in patientswith relapsed or treatment refractory solid tumor or brain tumor, and to determinethe best dose of ALRN-6924 for children and adolescents. This study will alsolook at how the body breaks down ALRN-6924 by measuring the amount of ALRN-6924in the blood over time after a dose.
The purpose of this studyis to determine the highest safe dose of abemaciclib in patients with relapsedor treatment refractory solid tumors given in combination with the chemotherapydrugs, irinotecan and temozolomide (Part A) or in combination with just temozolomide(Part B).